<DOC>
	<DOCNO>NCT00083057</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , paclitaxel , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving gefitinib paclitaxel together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gefitinib paclitaxel give together radiation therapy treat patient advanced recurrent squamous cell carcinoma ( cancer ) head neck .</brief_summary>
	<brief_title>Gefitinib , Paclitaxel , Radiation Therapy Treating Patients With Advanced Recurrent Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity , toxicity profile , maximum tolerate dose ( MTD ) gefitinib paclitaxel administer radiotherapy patient advance recurrent squamous cell carcinoma head neck . Secondary - Determine efficacy regimen patient treat MTD . OUTLINE : This pilot , dose-escalation study gefitinib paclitaxel . Patients receive oral gefitinib daily begin day 1 continue completion radiotherapy . Patients receive paclitaxel IV 1 hour day 8 , 15 , 22 , 29 , 36 , 43 undergo radiotherapy daily day 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 , 50-54 , 57-61 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gefitinib paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A cohort 6 additional patient receive treatment MTD . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 3 year . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell ( epidermoid ) carcinoma oral cavity , oropharynx , hypopharynx , larynx , nasopharynx , maxillary sinus Stage III IV disease Distant metastases allow provide follow true : Metastases confine head neck region Metastases encompassable radiotherapy field curative intent Locally recurrent disease primary surgery allow Meets 1 follow criterion : Unresectable disease Patient prefers chemoradiotherapy surgery Measurable disease No brain metastasis and/or carcinomatous meningitis PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Hemoglobin &gt; 10 g/dL Platelet count &gt; 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin &lt; 2.0 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN Renal Creatinine &lt; 1.5 time ULN OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Pulmonary No clinically active interstitial lung disease Chronic , stable , asymptomatic radiographic change allow Other No prior allergic reaction attribute compound similar chemical biological composition study drug Cremophor^® EL No AIDS primary immunodeficiency No malignancy within past 5 year except curatively treat squamous cell basal cell skin cancer carcinoma situ cervix Probability recurrence prior malignancy &lt; 5 % No concurrent uncontrolled illness No ongoing active serious infection No psychiatric illness situation would preclude study compliance give inform consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy cancer No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior therapeutic radiotherapy head neck region No prior radiotherapy cancer Surgery See Disease Characteristics At least 4 week since prior major surgery recover Other No prior gefitinib epidermal growth factor receptor inhibitor More 4 week since prior nonapproved investigational agent No concurrent administration follow : Phenytoin Carbamazepine Barbiturates Rifampin Hypericum perforatum ( St. John 's wort ) Oxcarbazepine Rifapentine Amifostine Modafinil Other CYP3A4 enzyme inducer Other anticancer agent investigational drug Combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>